Adaptive Biotechnologies announced that it has signed a biomarker discovery agreement facilitated by the Johnson & Johnson Innovation Centre in California. According to the agreement, Adaptive will use its patented immune profiling assay, immunoSEQTM, to allow an in-depth characterisation of the immune response to diseases being studied and select immunology and oncology drugs being developed by Janssen Research & Development LLC.